Evidence map›Paper›PMID 32720751›Full record

ArticleStem cells translational medicine2020

Combination product of dermal matrix, human mesenchymal stem cells, and timolol promotes diabetic wound healing in mice.

Hsin-Ya Yang, Fernando Fierro, Michelle So, Daniel J Yoon, Alan Vu Nguyen, Anthony Gallegos, Michelle D Bagood, Tomas Rojo-Castro, Alan Alex, Heather Stewart and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Hsin-Ya YangDepartment of Dermatology, University of California, Davis, Sacramento, California, USA.ORCID 0000-0002-5325-494X
Fernando FierroDepartment of Cell Biology and Human Anatomy, University of California, Davis, Sacramento, California, USA.
Michelle SoDepartment of Dermatology, University of California, Davis, Sacramento, California, USA.
Daniel J YoonDepartment of Dermatology, University of California, Davis, Sacramento, California, USA.
Alan Vu NguyenDepartment of Dermatology, University of California, Davis, Sacramento, California, USA.ORCID 0000-0002-2249-7244
Anthony GallegosDepartment of Dermatology, University of California, Davis, Sacramento, California, USA.
Michelle D BagoodDepartment of Dermatology, University of California, Davis, Sacramento, California, USA.
Tomas Rojo-CastroDepartment of Biological Sciences, California State University, Sacramento, Sacramento, California, USA.
Alan AlexDepartment of Biological Sciences, California State University, Sacramento, Sacramento, California, USA.
Heather StewartStem Cell Program, Department of Internal Medicine, University of California, Davis, Davis, California, USA.
Marianne ChigbrowDepartment of Dermatology, University of California, Davis, Sacramento, California, USA.
Mohan R DasuDepartment of Dermatology, University of California, Davis, Sacramento, California, USA.
Thomas R PeavyDepartment of Biological Sciences, California State University, Sacramento, Sacramento, California, USA.
Athena M SoulikaDepartment of Dermatology, University of California, Davis, Sacramento, California, USA.
Jan A NoltaStem Cell Program, Department of Internal Medicine, University of California, Davis, Davis, California, USA.
R Rivkah IsseroffDepartment of Dermatology, University of California, Davis, Sacramento, California, USA.ORCID 0000-0001-7813-0858
University of California, Davis · USCalifornia State University, Sacramento · USShriners Hospitals for Children - Northern California · USVA Northern California Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic foot ulcers are a major health care concern with limited effective therapies. Mesenchymal stem cell (MSC)-based therapies are promising treatment options due to their beneficial effects of immunomodulation, angiogenesis, and other paracrine effects. We investigated whether a bioengineered scaffold device containing hypoxia-preconditioned, allogeneic human MSCs combined with the beta-adrenergic antagonist timolol could improve impaired wound healing in diabetic mice. Different iterations were tested to optimize the primary wound outcome, which was percent of wound epithelialization. MSC preconditioned in 1 μM timolol at 1% oxygen (hypoxia) seeded at a density of 2.5 × 10

Indexed as

AnimalsDiabetes Mellitus, ExperimentalDisease Models, AnimalHumansImmunophenotypingMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceTimololWound HealingTimololanimal modelsdiabeteshypoxiamesenchymal stem/stromal cells (MSCs)

Identifiers

PMID32720751
PMCPMC7581456
OpenAlexW3045653173

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.